Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 30.83 USD 2.09% Market Closed
Market Cap: 1.8B USD

EV/EBIT
Enterprise Value to EBIT

1.4
Current
-2.1
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
1.4
=
Enterprise Value
891.3m USD
/
EBIT
648.8m USD
EBIT Growth EV/EBIT to Growth
US
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Average EV/EBIT: 17.3
1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 350.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.6
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -308.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.8
2-Years Forward
EV/EBIT
-1.9
3-Years Forward
EV/EBIT
-2.8